Lifelong Revenue vs. Short-Term Therapy
Detransitioners repeatedly point out that a short course of psychotherapy brings in far less money than keeping someone on prescriptions, check-ups, and surgeries for decades. “A few years of therapy doesn’t bring in as much revenue as a lifetime of hormones, a couple of big-ticket surgeries, and all the follow-ups those things require.” – Blutarg source [citation:4b677988-b6be-4cd8-a7d4-7def741ec218] Because every injection, blood test, and revision surgery is billable, the financial gap between the two approaches keeps widening.

Replacing One Market with Another
When the once-lucrative estrogen-for-menopause market collapsed in the late 1990s, drug makers looked for a new pool of lifelong customers. “Hormone replacement therapy used to take place as the routine administration of estrogen to menopausal women … prescriptions vanished overnight. Pharmaceutical companies … found a new market … the side effects of prolonged usage create life-long patients and even more profit.” – IKnowWhatImAbout source [citation:1e752fd3-229e-47e9-a0e2-52ada3cd0393] Testosterone, puberty blockers, and repeated cosmetic procedures now fill the revenue hole left by menopausal HRT.

Fear Overrules Clinical Judgement
Several posters describe doctors who agree to transition plans not because they believe it is best, but because refusal risks professional ruin. “Doctors will encourage and affirm 100 % of the time because they are making a lot of money … Being labeled transphobic is also a career-ender for them these days, so better to agree than question, ever.” – TreePangolin source [citation:7e6b3ba0-ae48-4a98-98ba-529a39d38b2b] In this climate, offering open-ended therapy or encouraging gender non-conformity can feel riskier to a clinician than writing the first prescription.

The Same Playbook as ADHD and Diet Drugs
Detransitioners see the same tactics used for stimulants and weight-loss injections: expand the diagnosis, normalize lifelong use, then harvest the recurring sales. “There’s huge money in having patients on drugs their entire lives … They did it first with psychiatry … or the weight-loss drugs, telling people you need to be on them for life.” – Affectionate_Act7962 source [citation:41774432-8875-4d19-a503-0c661dd21492] Each new “identity” label widens the customer base under the guise of compassion.

Conclusion
These voices do not deny the distress of gender dysphoria; instead, they highlight how financial incentives can quietly steer care toward endless medicalization rather than toward the less profitable—but often sufficient—work of self-exploration, supportive therapy, and joyful gender non-conformity. Understanding these pressures can empower you to ask critical questions, seek unbiased counseling, and remember that living authentically does not require a lifetime prescription.